Jade Biosciences
JBIO
49 hedge funds and large institutions have $403M invested in Jade Biosciences in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 25 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
9% more funds holding
Funds holding: 45 → 49 (+4)
0.02% less ownership
Funds ownership: 3.04% → 3.02% (-0.02%)
15% less capital invested
Capital invested by funds: $475M → $403M (-$72.5M)
72% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$6M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$1.7M |
| 3 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$577K |
| 4 |
PL
Parkwood LLC
Cleveland,
Ohio
|
+$442K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$334K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$6.35M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.36M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.16M |
| 4 |
BlackRock
New York
|
-$567K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$514K |
JBIO Hedge Fund Activity: Q2 2022 in Review
49 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q2 2022, worth a combined $403M — down 15% from $475M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new JBIO positions and 2 closed out — a net gain of 6 holders — while 7 added to existing stakes and 25 trimmed.
The largest buyer was VR Adviser, adding an estimated $6M. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $6.35M.
- 49 institutional investors held Jade Biosciences (JBIO) as of Q2 2022, up from 45 in Q1 2022.
- Funds reported $403M of Jade Biosciences stock for Q2 2022, down 15% quarter-over-quarter.
- 8 funds opened new Jade Biosciences positions in Q2 2022 and 2 closed out, a net change of +6 holders.
- The largest Jade Biosciences buyer in Q2 2022 was VR Adviser, an estimated $6M added.
- The largest Jade Biosciences seller in Q2 2022 was Atlas Venture Life Science Advisors, an estimated $6.35M sold.
Based on aggregated 13F filings for Q2 2022.